Results 121 to 130 of about 9,912 (208)

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS). [PDF]

PLoS One
Xiong W, Li Y, Huang J, He G, Sun J.
europepmc   +1 more source

Comparative Evaluation of the Effects of Oral Anti-hyperglycemic Agents and an Ayurvedic Hepatoprotective Agent in a Rat Model of Non-alcoholic Fatty Liver Disease (NAFLD). [PDF]

Cureus
Kalra SSS, Sadasivam B, Najmi A, Chaurasia JK.   +3 more
europepmc   +1 more source

Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? [PDF]

, 2015

core   +1 more source

Correction: Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity. [PDF]

Sci Rep
Samad A, Shahid S, Mansoor S, Afzal S, Javed M, Zidan A, Shoaib A, Jaber F, Iqbal S, Saad M, Mahmood S, Awwad NS, Ibrahium HA.   +12 more
europepmc   +1 more source

Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study. [PDF]

Cureus
Sanghvi A, Warrier S.
europepmc   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source

Association Between DPPs-4 Inhibitors and Bullous Pemphigoid: Reporting Odds Ratio Analysis Using EudraVigilance Database. [PDF]

Pharmaceuticals (Basel)
Pedrero AC, Aldea-Perona A.
europepmc   +1 more source

Genetic variants associated with glycemic and weight loss response to vildagliptin as add-on therapy to metformin in Egyptian obese type 2 diabetic patients: potential consequences on cardiac risk factors. [PDF]

Eur J Med Res
Saber K, Ismail R, Bassyouni A, El-Shafee M, Hassan MH.   +4 more
europepmc   +1 more source

Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications [PDF]

, 2015

core   +1 more source